The lower your bad cholesterol level goes, the fewer heart attacks and heart-related deaths you’re likely to have — and this effect is even stronger if you’ve already had a heart problem before.
Scientific Claim
Lower achieved LDL-C levels are associated with lower rates of major coronary events (coronary death or myocardial infarction) in both primary and secondary prevention populations, with a greater absolute benefit in secondary prevention.
Original Statement
“The achieved absolute LDL-C level was significantly associated with the absolute rate of major coronary events (11 301 events, including coronary death or MI) for primary prevention trials (1.5% lower event rate [95% CI, 0.5%-2.6%] per each 1-mmol/L lower LDL-C level; P = .008) and secondary prevention trials (4.6% lower event rate [95% CI, 2.9%-6.4%] per each 1-mmol/L lower LDL-C level; P < .001).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The abstract reports statistically significant associations with confidence intervals and p-values; however, without full RCT methodology verification, causal language is avoided per guidelines.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aIn EvidenceThat lower achieved LDL-C levels causally reduce major coronary events in a dose-dependent manner, stratified by primary vs. secondary prevention.
That lower achieved LDL-C levels causally reduce major coronary events in a dose-dependent manner, stratified by primary vs. secondary prevention.
What This Would Prove
That lower achieved LDL-C levels causally reduce major coronary events in a dose-dependent manner, stratified by primary vs. secondary prevention.
Ideal Study Design
A meta-analysis of RCTs with individual patient data, comparing achieved LDL-C levels (measured at 1, 3, and 5 years) to incidence of coronary death or MI, stratified by baseline cardiovascular risk (primary vs. secondary prevention), with adjustment for time-varying covariates.
Limitation: Cannot prove whether very low LDL-C (<0.5 mmol/L) has diminishing returns or adverse effects.
Randomized Controlled TrialLevel 1bThat targeting lower LDL-C levels (e.g., <1.0 mmol/L vs. 1.8 mmol/L) reduces coronary events more in secondary prevention patients.
That targeting lower LDL-C levels (e.g., <1.0 mmol/L vs. 1.8 mmol/L) reduces coronary events more in secondary prevention patients.
What This Would Prove
That targeting lower LDL-C levels (e.g., <1.0 mmol/L vs. 1.8 mmol/L) reduces coronary events more in secondary prevention patients.
Ideal Study Design
A double-blind RCT of 8,000 patients with prior MI, randomized to intensive LDL-C target (<1.0 mmol/L) vs. standard target (1.8 mmol/L), using PCSK9 inhibitors or statins, with primary outcome: time to first coronary death or MI over 5 years.
Limitation: Ethical and practical challenges in achieving very low LDL-C without long-term safety data.
Prospective Cohort StudyLevel 2bThat in real-world settings, patients who achieve lower LDL-C levels have fewer coronary events over time, especially if they have prior cardiovascular disease.
That in real-world settings, patients who achieve lower LDL-C levels have fewer coronary events over time, especially if they have prior cardiovascular disease.
What This Would Prove
That in real-world settings, patients who achieve lower LDL-C levels have fewer coronary events over time, especially if they have prior cardiovascular disease.
Ideal Study Design
A prospective cohort of 15,000 patients with and without prior MI, tracked for 10 years with serial LDL-C measurements and adjudicated coronary events, adjusting for medication adherence and comorbidities.
Limitation: Cannot distinguish whether lower LDL-C causes benefit or is a marker of better overall care.
Evidence from Studies
Supporting (1)
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.
This big study found that the lower your 'bad' cholesterol (LDL-C) goes, the fewer heart attacks and heart-related deaths you have — and this effect is even stronger in people who already had a heart problem.